Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity reactions involve IgG and IgM antibodies that bind to antigens on host cell surfaces. These antibodies trigger complement activation or recruit cytotoxic cells, leading to targeted cell destruction. This mechanism distinguishes Type II reactions from other hypersensitivity types.

In opsonization, antibodies like IgG mark target cells for clearance by phagocytes. Phagocytes recognize these antibody-tagged cells and engulf them, digesting the marked cells. This process is a key mechanism through which Type II hypersensitivity reactions eliminate host cells and cause tissue damage.

Penicillin binds to red blood cell surfaces, forming drug-protein complexes. Antibodies recognize these complexes and activate complement, causing RBC lysis. This drug-induced hemolytic anemia is a classic example of Type II hypersensitivity, and withdrawal of the drug typically resolves the condition.

When IgG and IgM antibodies bind to cell surface antigens, they activate complement components. This cascade leads to cell lysis and destruction of the targeted cells. Complement activation is one of the primary mechanisms driving tissue damage in Type II hypersensitivity reactions.

The Coombs test detects antibodies bound to red blood cell surfaces, indicating an immune attack on RBCs. This test is valuable for diagnosing drug-induced hemolytic anemia caused by medications like methyldopa or penicillin. A positive result confirms antibody-mediated destruction of red blood cells.

Type II hypersensitivity involves IgG and IgM antibodies causing immediate cell destruction through complement or cytotoxic mechanisms. In contrast, delayed hypersensitivity reactions are T-cell mediated and occur hours to days after exposure. These represent distinct immune pathways with different timelines and cellular players.

When drugs like penicillin or cephalosporins bind to cell surfaces, they create drug-protein complexes that the immune system recognizes as foreign antigens. The body produces antibodies against these complexes, which then bind and activate complement or recruit cytotoxic cells, resulting in cell destruction.